Latest Channelopathy Stories

2008-08-19 06:00:16

Research and Markets (http://www.researchandmarkets.com/research/8e04b4/cystic_fibrosis_w) has announced the addition of Decision Resources, Inc.'s new report "Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?" to their offering.

2008-07-14 09:00:14

WALTHAM, Mass., July 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in 2007, the United States market for the treatment of pulmonary symptoms of cystic fibrosis reached $397 million, reflecting primarily sales of Genentech/Roche's Pulmozyme and Novartis's antibiotic Tobi.

2008-07-09 12:00:49

HUNTINGTON BEACH, Calif., July 9 /PRNewswire-USNewswire/ -- Amazingly, surfers have unknowingly held a key to prolonging the lifespan and quality of life for people with cystic fibrosis (CF), a fatal genetic disease that causes the body to produce thick, sticky mucus, which clogs the lungs and leads to life-threatening lung infections.

2008-07-08 09:01:11

FoldRx Pharmaceuticals, Inc. (FoldRx) today announced that it has discovered a series of novel drug prototypes that have shown potential in vitro to correct the protein-folding defect associated with cystic fibrosis (CF).

2008-06-30 15:03:02

Case Western Reserve University School of Medicine, in collaboration with Copernicus Therapeutics, Inc.

2008-06-30 09:02:20

Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced positive results from an open-label, two week efficacy and safety study of its once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis (CF).

2008-06-26 06:02:10

By Knott, Laurence THE BASICS Proactive management can improve patient survival. By Dr Laurence Knott Cystic fibrosis (CF) affects one in 2,500 newborns and has a UK prevalence of 8,000.

2008-06-16 12:01:05

Altus Pharmaceuticals has announced the completion of the last patient visit of the Trizytek Phase III efficacy trial. In this trial, Altus is evaluating the efficacy of an oral, non-porcine enzyme replacement therapy for cystic fibrosis patients with exocrine pancreatic insufficiency.

2008-06-14 06:00:00

Cystic fibrosis is the most common genetic disease in Caucasians. The median life span for those with this malady is 36 years, and lung disease is the major cause of mortality.

2008-04-07 10:00:00

U.S. researchers say up to 100 million people globally have genetic mutations that keep their blood pressure low and lower their risk of heart and kidney disease and stroke.

Latest Channelopathy Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »
Word of the Day
  • totally perplexed and mixed up.
The word 'metagrabolized' is also spelled 'metagrobolized'.